Department of General Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Methods Mol Biol. 2023;2695:227-236. doi: 10.1007/978-1-0716-3346-5_15.
Colorectal cancer (CRC) is a very common gastrointestinal tumor, ranking second in the global cause of cancer death. Because of the invasive nature of biopsy and cannot reflect the heterogeneity of tumor or monitor the dynamic progress of tumor, it is necessary to induce a novel noninvasive method to improve the current treatment strategies of colorectal cancer. Among all the components of liquid biopsy, circulating tumor DNA (ctDNA) may have the best future. CtDNA maintains the same genomic characteristics as those in matched tumor tissues, so it allows quantitative evaluation and analysis of mutation load in body fluid. Furthermore, because the half-life of ctDNA is from 16 min to several hours in circulation, the circulating ctDNA can be measured repeatedly within a certain period to monitor the response of CRC to treatment, the occurrence of drug resistance, and the diagnosis of recurrence.
结直肠癌（CRC）是一种非常常见的胃肠道肿瘤，在全球癌症死亡原因中排名第二。由于活检具有侵袭性，无法反映肿瘤的异质性或监测肿瘤的动态进展，因此有必要诱导一种新的非侵入性方法来改进结直肠癌的当前治疗策略。在所有液体活检的成分中，循环肿瘤 DNA（ctDNA）可能具有最好的应用前景。ctDNA 保持与匹配的肿瘤组织相同的基因组特征，因此允许对体液中的突变负荷进行定量评估和分析。此外，由于 ctDNA 在循环中的半衰期为 16 分钟至数小时，因此可以在一定时间内反复测量循环中的 ctDNA，以监测 CRC 对治疗的反应、耐药的发生以及复发的诊断。
